Chemomab Therapeutics

Historical price data

Chemomab Therapeutics' mission is to develop first-in-class antibody therapies targeting the CCL24 pathway to halt fibrosis and inflammation in diseases with significant unmet need. Its key achievement is the advancement of its lead asset, CM-101, into mid-stage clinical trials for three distinct fibrotic indications. The company's strategy is to generate compelling Phase 2 proof-of-concept data to validate CCL24 as a therapeutic target and attract partnership or further development capital. As a micro-cap public company, its near-term fate is tightly coupled to the binary outcomes of these clinical readouts.

Platform centered on neutralizing the CCL24 chemokine, a soluble protein identified as a master regulator driving both inflammatory and fibrotic processes across multiple organ systems.

CM-101 is first-in-class targeting CCL24, providing mechanistic differentiation. It faces distinct competition in each indication: in systemic sclerosis against IL-6 and CD20 inhibitors; in PSC against FXR/PPAR agonists in a field with no approved drugs; and in the highly crowded MASH landscape against major pharma players.